NCT03066206 - Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 17, 2017

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

EGFR Exon 20 MutationERBB2 Gene MutationRecurrent Lung Non-Small Cell CarcinomaStage IV Non-Small Cell Lung Cancer AJCC v7

Interventions

DRUG

Poziotinib

Given PO

Trial Locations (1)

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

collaborator

Spectrum Pharmaceuticals, Inc

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER